Journal of Clinical Endocrinology & Metabolism, Vol 80, 1628-1634, Copyright © 1995 by Endocrine Society

ARTICLES

Oncogenic osteomalacia: evidence for a humoral phosphaturic factor

GE Wilkins, S Granleese, RG Hegele, J Holden, DW Anderson and GP Bondy
Department of Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.

Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia. The cause is not known, but all patients have had a tumor; usually of mesenchymal origin. Removal of the tumor reverses the metabolic abnormalities. We report a patient with osteomalacia, severe hypophosphatemia, elevated alkaline phosphatase, low 1,25-dihydroxyvitamin D3, and phosphaturia. A tumor was identified in the infratemporal fossa. The tumor was removed, and all of the biochemical abnormalities resolved over the subsequent 8 months. The bone density returned to normal values. The tumor had the appearance of a paraganglioma and was used to establish a cell culture line called JH-55. Electron microscopy of the original tumor and the JH- 55 cells demonstrated the presence of neurosecretory granules. A bioassay using opossum kidney cells was used to evaluate phosphate transport. Conditioned medium from the JH-55 cells inhibited phosphate reabsorption by the kidney tubular cells. Maximal inhibition required a 24-h incubation period and was not altered by the presence of an inhibitor of protein synthesis (10 micrograms/mL cycloheximide). Immunoassays revealed no detectable PTH-related peptide or intact PTH in the JH-55 medium. The cause of this paraneoplastic syndrome is not known, but all of the evidence is consistent with the action of a hormone that produces phosphaturia. This putative factor is distinct from other hormones that cause phosphaturia.

This article has been cited by other articles:

				M. Mannstadt, C. Lorente, and H. Juppner Rapid Detection of Intact FGF-23 in Tumor Tissue from Patients with Oncogenic Osteomalacia Clin. Chem., July 1, 2008; 54(7): 1252 - 1254. [Full Text] [PDF]

				S. M. Jan de Beur Tumor-Induced Osteomalacia JAMA, September 14, 2005; 294(10): 1260 - 1267. [Abstract] [Full Text] [PDF]

				D. Bresler, J. Bruder, K. Mohnike, W. D Fraser, and P. S N Rowe Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets J. Endocrinol., December 1, 2004; 183(3): R1 - R9. [Abstract] [Full Text] [PDF]

				P. S.N. Rowe THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX Crit. Rev. Oral. Biol. Med., September 1, 2004; 15(5): 264 - 281. [Abstract] [Full Text] [PDF]

				A. E. Nelson, R. C. Bligh, M. Mirams, A. Gill, A. Au, A. Clarkson, H. Juppner, S. Ruff, P. Stalley, R. A. Scolyer, et al. Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4088 - 4094. [Abstract] [Full Text] [PDF]

				S. M. Jan De Beur and M. A. Levine Molecular Pathogenesis of Hypophosphatemic Rickets J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2467 - 2473. [Full Text] [PDF]

				T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, S. Takeda, Y. Takeuchi, T. Fujita, S. Fukumoto, and T. Yamashita Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia PNAS, May 3, 2001; (2001) 101545198. [Abstract] [Full Text]

				S. J. Yeung, I. E. McCutcheon, P. Schultz, and R. F. Gagel Use of Long-Term Intravenous Phosphate Infusion in the Palliative Treatment of Tumor-Induced Osteomalacia J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 549 - 555. [Abstract] [Full Text]

				P. H. Dixon, P. T. Christie, C. Wooding, D. Trump, M. Grieff, I. Holm, J. M. Gertner, J. Schmidtke, B. Shah, N. Shaw, et al. Mutational Analysis of PHEX Gene in X-Linked Hypophosphatemia J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3615 - 3623. [Abstract] [Full Text]

				M. L. Lipman, D. Panda, H. P. J. Bennett, J. E. Henderson, E. Shane, Y. Shen, D. Goltzman, and A. C. Karaplis Cloning of Human PEX cDNA. EXPRESSION, SUBCELLULAR LOCALIZATION, AND ENDOPEPTIDASE ACTIVITY J. Biol. Chem., May 29, 1998; 273(22): 13729 - 13737. [Abstract] [Full Text] [PDF]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, S. Takeda, Y. Takeuchi, T. Fujita, S. Fukumoto, and T. Yamashita Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia PNAS, May 22, 2001; 98(11): 6500 - 6505. [Abstract] [Full Text] [PDF]